NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation
NAMS•BROADWAY AD biomarker substudy findings
In the Phase 3 BROADWAY AD biomarker substudy, 12 months of obicetrapib reduced plasma p-tau217 versus placebo, strongest in APOE4/E4 carriers.
Other biomarker shifts support prevention-trial rationale
The presentation also cited favorable shifts across other Alzheimer’s-related biomarkers, supporting a rationale for prevention trials in at-risk APOE4 populations.
Research presentation on CETP inhibition and Alzheimer’s prevention
NewAmsterdam Pharma published a research presentation on CETP inhibition for Alzheimer’s prevention, centered on its CETP inhibitor obicetrapib.
